Tempest Therapeutics, Inc. (TPST) annual cash flow statement — 14-year operating, investing & financing history
Tempest Therapeutics, Inc. (TPST) cash flow statement — 14-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|
| Cash from Operations | -20.73M | -26.82M | -33.03M | -27.36M | -31.07M | -25.96M | -19.02M | -41.22M | -23.65M | -20.34M | -61.73M | -50.29M | -30.59M | -18.09M | -11.16M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | -6894.92% | -9453.91% | -18153.79% | -314.21% | - | - |
| Operating CF Growth % | 170.7% | 18.79% | -20.73% | 11.96% | -19.71% | -36.49% | 53.87% | -74.32% | -16.26% | 67.05% | -22.77% | -64.4% | -69.05% | -62.19% | - |
| Net Income | -40.47M | -26.26M | -41.84M | -29.49M | -35.71M | -28.3M | -19.21M | -44.57M | -27.19M | -84.58M | -82.26M | -73.22M | -49.52M | -29.04M | -13.51M |
| Depreciation & Amortization | 251K | 266K | 389K | 381K | 638K | 374K | 339K | 1.05M | 32K | 1.65M | 2.24M | 1.29M | 450K | 231K | 93K |
| Stock-Based Compensation | 746K | 3.12M | 5.3M | 2.55M | 1.56M | 1.1M | 453K | 0 | 1.43M | 6.89M | 9.21M | 19.34M | 12.41M | 5.09M | 1.38M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -599K |
| Other Non-Cash Items | 22.8M | 1.19M | 1.51M | 1.88M | 1.57M | 1.48M | 470K | 4.35M | 0 | 66.05M | 0 | 0 | -6.33M | -3.8M | 879K |
| Working Capital Changes | -4.06M | -5.13M | 1.61M | -2.68M | 868K | -613K | -1.07M | -2.05M | 1.04M | -1.84M | 4.58M | -532K | 12.4M | 9.42M | 599K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -2.72M | -1.41M | 1.6M | -263K | 1K | -209K | -574K | -469K | 320K | -1.45M | -1.18M | -171K | 2.32M | -721K | 599K |
| Cash from Investing | 0 | 0 | -435K | -170K | -562K | -97K | -6K | 3.99M | 1.12M | 458K | 8.29M | -38.29M | -32.79M | -11.02M | -17.64M |
| Capital Expenditures | 0 | 0 | -435K | -170K | -562K | -135K | -50K | -397K | -36K | -158K | -2.59M | -5.23M | -2.8M | -719K | -849K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | 53.56% | 396.02% | 1887.73% | 28.8% | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.33M | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 38K | 44K | 0 | 0 | -1.45M | 0 | -681K | -1.61M | 5K | -93K |
| Cash from Financing | 7.23M | 4.26M | 24.5M | 35.6M | 11.4M | 59.06M | 34.6M | 26.94M | 78.55M | -4.46M | 54.15M | 125.39M | 51.71M | 32.41M | 39.03M |
| Debt Issued (Net) | 0 | -6.43M | -4.4M | 0 | -4.74M | 15M | 0 | -202K | 6.48M | -4.46M | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 7.23M | 10.69M | 28.59M | 35.6M | 16.14M | 33.42M | 35M | 27.14M | 38.76M | 2K | 54.15M | 125.39M | 51.71M | 32.41M | 39.03M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 307K | 0 | 0 | 10.64M | -401K | 0 | 33.32M | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | -13.5M | -22.56M | -8.96M | 8.07M | -20.23M | 33.01M | 15.58M | -9.82M | 55.71M | -26.31M | 706K | 37.01M | -11.66M | 3.3M | 10.23M |
| Free Cash Flow | -20.73M | -26.82M | -33.46M | -27.53M | -31.63M | -26.09M | -19.07M | -41.62M | -23.68M | -20.34M | -64.32M | -55.52M | -33.39M | -18.81M | -12.01M |
| FCF Margin % | - | - | - | - | - | - | - | - | - | -6896.27% | -9849.92% | -20041.52% | -343.01% | - | - |
| FCF Growth % | 43.69% | 19.85% | -21.56% | 12.98% | -21.24% | -36.84% | 54.19% | -75.73% | -16.41% | 68.37% | -15.86% | -66.25% | -77.49% | -56.71% | - |
| FCF per Share | -1.36 | -6.46 | -1.20 | -1.79 | -35.61 | -89.49 | -610.93 | -45.55 | -229.63 | -17417.81 | -450.17 | -461.18 | -331.75 | -186.91 | -6044.81 |
| FCF Conversion (FCF/Net Income) | 0.51x | 1.02x | 0.79x | 0.93x | 0.87x | 0.92x | 0.99x | 0.92x | 0.87x | 0.24x | 0.75x | 0.69x | 0.62x | 0.62x | 0.83x |
| Interest Paid | 0 | 192K | 1.18M | 1.25M | 1.54M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 21K | 43K | 54K | 191K | 18K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying TPST stock.
Tempest Therapeutics, Inc. (TPST) generated $-26.8M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Tempest Therapeutics, Inc. (TPST) reported negative free cash flow of $26.8M in 2025, indicating capital requirements exceeded cash from operations.
Tempest Therapeutics, Inc. (TPST) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.